A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit

Alida Fe Talento(Beaumont Hospital), Thomas R. Rogers(Scripps Research Institute), P. Lewis White(University Hospital of Wales), Jan Springer(Universitätsklinikum Würzburg), Daniel Collins(St. James's Hospital), Elizabeth M. Johnson(Bristol-Myers Squibb (Germany)), Katie Dunne(Trinity College Dublin), Eimear Joyce(St. James's Hospital), Michael Palmer(Queen's University), Thomas Ryan, Juergen Loeffler(Augenklinik Universitätsklinikum Würzburg)
Journal of Critical Care
March 30, 2017
10.1016/j.jcrc.2017.03.025
Cited by 34

Related Papers

ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary
|Journal of the American College of Cardiology|2002|1.7k
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
|Clinical Infectious Diseases|2003|680
Use of probiotic <i>Lactobacillus</i> preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial
|BMJ|2007|591
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
|Intensive Care Medicine|2020|464
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology
|The Lancet Infectious Diseases|2021|450